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This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).SUMMARYThere is considerable interest in differentiating human pluripotent stem cells (hPSCs) into definitive endoderm (DE) and pancreatic cells
for in vitro disease modeling and cell replacement therapy. Numerous protocols use fetal bovine serum, which contains poorly defined
factors to induce DE formation. Here, we comparedWnt and BMP in their ability to cooperate with Activin signaling to promote DE for-
mation in a chemically defined medium. Varying concentrations of WNT3A, glycogen synthase kinase (GSK)-3 inhibitors CHIR99021
and 6-bromoindirubin-30-oxime (BIO), and BMP4 could independently co-operate with Activin to effectively induce DE formation
even in the absence of serum. Overall, CHIR99021 is favored due to its cost effectiveness. Surprisingly, WNT3A was ineffective in sup-
pressing E-CADHERIN/CDH1 and pluripotency factor gene expression unlike GSK-3 inhibitors or BMP4. Our findings indicate that
bothWnt and BMP effectively synergize with Activin signaling to generate DE from hPSCs, althoughWNT3A requires additional factors
to suppress the pluripotency program inherent in hPSCs.INTRODUCTION
Human embryonic stem cells (hESCs) and human induced
pluripotent stem cells (hiPSCs), collectively known as hu-
manpluripotent stemcells (hPSCs), canpotentiallybediffer-
entiated into clinically useful cell types for in vitro disease
modeling, drug screening, and cell replacement therapy.
Given the explosion indiabetes and its complicationsworld-
wide, the directed differentiation of hPSCs into definitive
endoderm (DE) and subsequently pancreatic cells is of
immense interest (Teo et al., 2013a). In 2005, Novocell
(now ViaCyte) reported the ability to derive > 80% of DE
from hESCs with the use of 100 ng/ml Activin A (hereafter
referred to as ‘‘Activin’’) in the presence of 0.2%–2% fetal
bovine serum (FBS; D’Amour et al., 2005). To complement
Activin/Nodal signaling in inducing DE formation, Wnt
and BMP signaling activators were then introduced (Table
S1 available online). Developmentally, thismimics the com-
plexNodal,Wnt (Wnt3,Wnt3a andWnt5a) and Bmp (Bmp4)
signaling, which operate during gastrulation, primitive
streak, andearlyDE formation in themouse embryo (Arnold
and Robertson, 2009; Lawson et al., 1999; Liu et al., 1999;
Ohinata et al., 2009; Teo et al., 2011; Yamaguchi et al., 1999).
The coactivation of Wnt and Activin/Nodal signaling
(albeit in the presence of FBS) is commonly used as
described by D’Amour et al. (2006). They reported that Ac-
tivin andWNT3A (specifically 100 ng/ml Activin, 25 ng/ml
WNT3A, and 0.2% FBS) can induce more than 80% of DE
cells (D’Amour et al., 2006). Alternatively, activation of
Wnt signaling via the inhibition of glycogen synthase
kinase (GSK)-3 (specifically 100 ng/ml Activin or 500 nMIDE1, 3 mM CHIR99021 [GSK-3 inhibitor], and 2% FBS)
has also been recently reported to induce 70%–80% of DE
cells (Illing et al., 2013; Kunisada et al., 2012). In contrast,
the work of Teo, Dunn (Phillips et al., 2007; Teo et al.,
2012), and Vallier (Vallier et al., 2009) independently
demonstrated that 10–50 ng/ml of BMP4 can synergisti-
cally act with Activin (in a defined medium without FBS)
to inducemore than 80% of DE cells. However, it is still un-
certain how Wnt compares with BMP in cooperating with
Activin/Nodal signaling in a chemically definedmedium to
induce DE formation.
We sought to clarify and define the Activin-Wnt-BMP
signaling relationship using hiPSCs that we derived (Teo
et al., 2013b). Here, we report a head-to-head comparison
of Wnt versus BMP in combination with Activin signaling
in a chemically defined medium without FBS to induce DE
formation. Unlike previous reports (25 ng/ml WNT3A plus
FBS; Table S1), we observed that a high dose of WNT3A
(100 ng/ml, without FBS) is required to maximally induce
DE in the presence of 100 ng/ml Activin. The activation
of Wnt signaling with the use of two independent GSK-3
inhibitors (CHIR99021 or 6-bromoindirubin-30-oxime
[BIO]; Sato et al., 2004) or BMP signaling with BMP4 can
also maximally induce DE cells. Thus, both Wnt and BMP
signaling can effectively cooperate with Activin signaling
to induce DE formation.
Effective differentiation of hPSCs into DE is coupledwith
the suppression of E-CADHERIN/CDH1 and pluripotency.
Whereas BMP signaling has been reported to suppress
E-CADHERIN/CDH1 and pluripotency (Teo et al., 2011,
2012), we observed that WNT3A is not as effective asStem Cell Reports j Vol. 3 j 5–14 j July 8, 2014 j ª2014 The Authors 5
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and the pluripotency program. This could partly explain
the continued requirement for FBS when deriving DE
with WNT3A. Therefore, our study identifies the unprece-
dented need for an additional compound to suppress
pluripotency when combining Activin and WNT3A to
generate DE cells without serum.RESULTS
High Dose of WNT3A Is Sufficient to Cooperate with
Activin to Induce DE without Serum
Many previous studies have reported reliance upon Activin,
WNT3A, and FBS to differentiate hPSCs into DE (Table S1).
To determine whether WNT3A can cooperate with Activin
in a chemically defined medium in the absence of serum
(RPMI 2% B27) to induce DE from hiPSCs, we used
10–30 ng/ml WNT3A with 0–100 ng/ml Activin in optimi-
zation experiments. Dismally, 30 ng/ml WNT3A and
100 ng/ml Activin only marginally increase the expression
of DE markers SOX17 and FOXA2 (Figures 1A and 1C–1E).
Unlike previous reports, a low dose ofWNT3A is insufficient
to effectively promote DE formation in serum-free condi-
tions. We subsequently increased the dose of WNT3A
and determined that 100 ng/ml WNT3A can effectively
result in maximal DE marker gene expression (Figures 1B–
1E) without a dose-responsive increase in mesodermal
markers BRACHYURY and TBX6, or extraembryonic marker
SOX7 (Figure S1A). Morphologically, cells induced with
100 ng/ml Activin and 30 or 100 ng/ml WNT3A looked
indistinguishable but different from no growth factor
condition (Figure 1C). However, immunostaining and
quantitative analyses for SOX17 DE marker clearly demon-
strated that 100 ng/ml Activin + 100 ng/ml WNT3A gave
rise to DE cells with a comparable efficiency as that of
100 ng/ml Activin + 30 ng/ml WNT3A + 0.5% FBS, as
opposed to 100 ng/ml Activin + 30 ng/ml WNT3A (Figures
1D and 1E). Together, these findings suggest that FBS is
necessary for synergistic activity with 100 ng/ml ActivinFigure 1. A High Dose of WNT3A Is Required for Activin-Induced
(A and B) Expression of mesendoderm (EOMES, MIXL1) and DE (CXC
the presence of Activin (0, 25, 50, 100 ng/ml) and (A) low dose (10
Asterisk (*) indicates p < 0.05 compared to no growth factor (A0 W0
(C) Morphology of hiPSCs differentiated for 3 days in the presence of
either 30 ng/ml (W30; middle) or 100 ng/ml (W100; right) WNT3A. S
(D) Immunostaining for the SOX17 DE marker on hiPSCs differentiated
0.5% fetal bovine serum (FBS). Scale bar represents 50 mm.
(E) The percentage of SOX17+ cells after differentiation of hiPSCs for 3
0.5% FBS. Asterisk (*) indicates p < 0.05 compared to A100 W0. All e
WNT3A; and FBS, fetal bovine serum. DAPI is the nuclear stain.
See also Figure S1.and 25 ng/ml WNT3A to efficiently induce DE formation.
Thus, FBS + 25 ng/ml WNT3A can be replaced with a high
dose of WNT3A (100 ng/ml) to induce DE.
GSK-3 Inhibitors, CHIR99021 andBIO, Cooperatewith
Activin to Induce DE without Serum
To further define the synergism between Wnt and Activin
signaling in inducing DE without serum, we adopted com-
plementary approaches to activateWnt signaling by inhib-
iting the downstream signaling molecule GSK-3, using two
independent GSK-3 inhibitors, CHIR99021 or BIO, which
block the degradation of b-catenin, thereby allowing its
nuclear translocation and activation of downstream target
genes. Kunisada et al. (2012) and Illing et al. (2013) used a
GSK-3 inhibitor to demonstrate that 3 mMCHIR99021with
100 ng/ml Activin or 500 nM IDE1 and 2% FBS induces
70%–80% of DE cells.
Initially, we used a range of doses of CHIR99021 (0.5, 3,
or 9 mM) together with Activin to prompt DE differentia-
tion (Figure 2A). Interestingly, 9 mM CHIR99021 induces
maximal CXCR4 gene expression independent of the
requirement for Activin. However, cardinal DE markers
EOMES, SOX17, and FOXA2 are suppressed at such a dose,
suggesting that excessiveWnt signaling activation is refrac-
tory to DE formation (Figure 2A). Thus, we lowered the
doses of CHIR99021 to 1, 3, and 5 mM. Morphologically,
cells induced with 100 ng/ml Activin and 1 or 3 mM
CHIR99021 were indistinguishable but different from no
growth factor condition. We finally confirmed that 3 mM
CHIR99021 (together with 100 ng/ml Activin) maximally
induces DE differentiation in our chemically defined me-
dium (Figures 2B and 2C) without a dose-responsive in-
crease in mesodermal markers BRACHYURY and TBX6, or
extraembryonic marker SOX7 (Figure S1B). The increasing
dose of CHIR99021 increases mesodermal marker gene
expression independent of the dose of Activin (Figure S1B),
indicating a fine balance in its use for DE (1–3 mM) versus
mesoderm (>3 mM) formation.
Tocomplement theuseofCHIR99021 inderivingDEcells,
we used another GSK-3 inhibitor, BIO (0.5, 2, or 5 mM), toDE Formation in Absence of Serum
R4, SOX17, FOXA2) markers in hiPSCs differentiated for 3 days in
, 20, 30 ng/ml) or (B) high dose (50, 100, 200 ng/ml) of WNT3A.
).
no growth factors (A0 W0; left) or 100 ng/ml Activin (A100) plus
cale bar represents 200 mm.
for 3 days in the presence of A100 and WNT3A (W0, W30, W100) ±
days in the presence of A100, A100 W30, A100 W100, or A100 W30 +
rror bars represent SD of three biological replicates. A, Activin; W,
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Comparable DE formation via Wnt or BMP SignalingactivateWnt signaling and observed thatR2 mMresulted in
excessive cell death (data not shown). Subsequently we
determined that 1.5 mM BIO together with 100 ng/ml Acti-
vin is optimal for generating DE cells from hPSCs without
serum (Figure 2D), againwithout a dose-responsive increase
inmesodermalmarkers BRACHYURYandTBX6, or extraem-
bryonic marker SOX7 (Figure S1C).
Wnt and BMP Signaling Can Enhance Activin-
Induced DE with Comparable Efficiencies
without Serum Supplementation
Next, to confirm that BMP4 and Activin can induce DE
from hPSCs without serum, we performed similar dose-
response experiments. These experiments ascertained
that 100 ng/ml Activin and 25–50 ng/ml BMP4 can elicit
maximal expression of DE markers CXCR4, SOX17, and
FOXA2 (Figure 3A), without a dose-responsive increase in
mesodermal markers BRACHYURY and TBX6, or extraem-
bryonic marker SOX7 (Figure S1D). Because both Wnt
and BMP can cooperate with Activin signaling to generate
DE cells in our chemically defined differentiation condi-
tion, we then compared the various optimal DE-inducing
conditions in the same experiment. Time course analyses
indicated that Wnt and BMP signaling-based conditions
induced a peak expression of mesendodermal marker
EOMES between days 2 and 3 and DE markers CXCR4 and
SOX17 on day 3 in one hiPSC and one hESC line (Figures
S2A–S2C). Thus, we compared these DE-inducing condi-
tions on day 3 of differentiation.
Interestingly, the combination of 100 ng/ml Activin and
3 mM CHIR99021 resulted in the highest expression of
mesendoderm (EOMES, MIXL1) and DE (CXCR4, SOX17,
FOXA2) marker gene expression (Figure 3B), although the
percentage of SOX17+ DE cells (as determined by cell
count) is comparable with the other DE-inducing condi-
tions (Figures S3B and S3C). Fluorescence-activated cell
sorting (FACS) analyses performed on two different hPSC
lines further confirmed the observation that the various
optimal DE-inducing conditions generated comparable
percentages of CXCR4+SOX17+ DE cells (Figures 3C
and S3E). Reassuringly, cells differentiated in the optimal
DE-inducing conditions morphologically resembled each
other but were different from no growth factor conditionFigure 2. GSK-3 Inhibitors CHIR99021 and BIO Can Promote DE F
(A and B) Expression of mesendoderm (EOMES, MIXL1) and DE (CXCR4
presence of Activin (0, 25, 50, 100 ng/ml) and (A) wide range (0.5,
(C) Morphology of hiPSCs differentiated for 3 days in the presence of no
1 mM (C1; middle) or 3 mM (C3; right) CHIR99021. Scale bar represen
(D) Expression of mesendoderm and DE markers in hiPSCs differentiated
(0.5, 1, 1.5 mM). Asterisk (*) indicates p < 0.05 compared to no gr
biological replicates. A, Activin; C, CHIR99021.
See also Figure S1.(Figure S3D). Among the optimal DE-inducing conditions,
3 mM CHIR99021 induced mesendodermal marker BRA-
CHYURY and a marginal increase in mesodermal marker
TBX6 but none of them induced extraembryonic tissue
marker SOX7 dramatically (Figure S3A).
To further ascertain that the various optimal DE-
inducing conditions were comparable with published
methods, we undertook a head-to-head comparison with
protocols outlined in Kroon et al. (2008) and Touboul
et al. (2010), using the same differentiation medium
(RPMI 2% B27). Because Touboul et al. (2010) utilized
20 ng/ml FGF2 (F20) and 10 mM LY294002 (LY10) in addi-
tion to Activin and BMP4, we applied the same amount of
FGF2 and LY294002 to all our DE-inducing conditions
because the aim was to determine if the various Wnt and
BMP signaling-induced DE (in the presence of 100 ng/ml
Activin) were comparable with published methods. In our
comparison performed on two different hPSC lines, we
found that our various optimal DE-inducing conditions
were comparable with Touboul et al. (2010) and at times
superior to Kroon et al. (2008) in terms of the induction
of DE (CXCR4, SOX17, FOXA2) marker gene expression
(Figure S4A).
Next, we investigated whether our DE-inducing condi-
tions generated DE derivatives comparably. To this end, we
differentiated these DE cells into pancreatic progenitors us-
ing a published protocol (Teo et al., 2012) with somemodifi-
cations (A.K.K.T. et al., unpublished data). Our DE-inducing
conditions gave rise to pancreatic progenitor markers SOX9
and PDX1 comparably with Kroon et al. (2008) in two
different hPSC lines (Figure S4B), demonstrating equiva-
lence in terms of their differentiation potential.
Wnt Signaling via WNT3A Is Not as Effective as BMP4
or the GSK-3 Inhibitors, CHIR99021 and BIO, in
Suppressing E-CADHERIN and Pluripotency of hPSCs
during DE Induction
During DE differentiation, hPSCs undergo epithelial to
mesenchymal transition evidenced by morphological
changes (Figures 1C, 2C, and S3D) and a decrease in epithe-
lial marker E-CADHERIN/CDH1 (D’Amour et al., 2005). In
addition, pluripotency program is suppressed, with rapid
plummeting of pluripotency factor SOX2 expressionormation
, SOX17, FOXA2) markers in hiPSCs differentiated for 3 days in the
3, 9 mM) or (B) narrow range (1, 3, 5 mM) of CHIR99021.
growth factors (A0 C0; left) or 100 ng/ml Activin (A100) plus either
ts 200 mm.
for 3 days in the presence of Activin (0, 25, 50, 100 ng/ml) and BIO
owth factor (A0 C0, A0 Bio0). All error bars represent SD of three
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Comparable DE formation via Wnt or BMP Signalingfollowed by NANOG and lastly OCT4 (Teo et al., 2011,
2012). To ascertain that both Wnt and BMP signaling-
induced DE cells are committed toward DE cell fate, we
investigated the impact of varying doses of Wnt and BMP
signaling activators on epithelial marker E-CADHERIN/
CDH1 and pluripotency factor gene expression. Despite a
high dose of WNT3A being able to significantly induce DE
marker gene expression (with 100 ng/ml Activin), the
expression level of E-CADHERIN/CDH1 did not decrease
with increasing doses of WNT3A (Figure 4A). Surprisingly,
pluripotency factors SOX2 and NANOG were only margin-
ally affected by increasing doses of WNT3A with a back-
ground of 100 ng/ml Activin (Figures 4A–4C). In contrast,
increasing doses of BMP4 and GSK-3 inhibitors,
CHIR99021 and BIO, resulted in significant suppression of
E-CADHERIN/CDH1 and pluripotency factors SOX2 and
NANOG (Figures 4A–4C). Collectively, these data suggest
that additional factors are required to work with WNT3A
to suppress E-CADHERIN/CDH1 and pluripotency factors
during differentiation toward DE. Therefore, CHIR99021,
BMP4, and BIO may be preferred for DE differentiation
because theyalso aid in the suppressionofpluripotency (Fig-
ures 4A–4C).DISCUSSION
We report the use of a chemically defined differentiation
medium to compare DE-inducing effects by Wnt or BMP
signaling in the presence of Activin signaling. This direct
comparison demonstrates that both Wnt and BMP can
independently synergize with Activin signaling to compa-
rably and effectively induce DE cells from hPSCs in the
absence of FBS. Numerous reports have established that
25 ng/ml WNT3A is optimal for inducing DE in the pres-
ence of Activin and FBS (Table S1). However, 10–30 ng/ml
WNT3A is insufficient to synergize with 100 ng/ml Activin
to effectively generate DE cells in our serum-free system.
The need for 100 ng/ml WNT3A for efficient DE formation
in a chemically defined system suggests that FBS (which ex-
hibits batch-to-batch variability) introduces additional dif-
ferentiation-promoting factors to supplement 25 ng/ml
WNT3A in inducing DE cells.Figure 3. Activators of Wnt and BMP Signaling Can Enhance Activ
(A and B) Expression of mesendoderm (EOMES, MIXL1) and DE (CXCR4
presence of (A) Activin (0, 25, 50, 100 ng/ml) and BMP4 (0, 25, 50 ng
A100 plus either 25 ng/ml BMP4 (B25), 100 ng/ml WNT3A (W100), 3
p < 0.05 compared to no growth factor (A0 B0, A0). All error bars rep
(C) The percentage of CXCR4+SOX17+ DE cells determined by FACS anal
3 days in the presence of A100 B25, A100 W100, A100 C3, A100 Bio
CHIR99021; FBS, fetal bovine serum.
See also Figures S1–S4 and Table S1.Although Kunisada et al. (2012) and Illing et al. (2013)
used CHIR99021 to induce DE differentiation from hPSCs,
they also included FBS in their protocol. We now provide
several alternative methods for effectively inducing DE
cells, all via the activation of Wnt signaling pathway (in
addition to the indispensable Activin signaling pathway).
These include 100 ng/ml WNT3A, 3 mM CHIR99021, and
1.5 mMBIO, all of which exhibit similar effects inDE induc-
tion. This three-pronged approach confirms the ability of
Wnt to synergize with Activin signaling to induce DE in a
chemically defined medium. Our comparison with Kroon
et al. (2008) (WNT3A-based) and Touboul et al. (2010)
(BMP4-based) further demonstrates that these three Wnt
signaling-based optimized conditions induce DE compa-
rably and efficiently, and give rise to DE derivatives with
equivalent potential.
However, it is surprising to note that WNT3A is not as
effective in downregulating E-CADHERIN/CDH1 and plu-
ripotency factors as compared to GSK-3 inhibitors (or even
BMP4) in a serum-free system. It is known from early
mammalian development that the expression of Oct4, and
in particular Sox2 and Nanog (Avilion et al., 2003; Hart
et al., 2004) coincides with the in situ expression of Wnt3,
Wnt3a andWnt5a but not that of Bmp4 (Arnold and Robert-
son, 2009; Liu et al., 1999; Tam and Loebel, 2007; Teo et al.,
2011; Yamaguchi et al., 1999). Thus, given the overlapping
expression of Wnt and pluripotency genes but not that of
Bmp, it is conceivable that Wnt does not play a major role
in suppressingpluripotency incontrast toBMP. In this study,
we reveal fundamentalmechanistic differences between the
two developmental signaling pathways: (1) BMP signaling
suppresses pluripotency and simultaneously promotes DE
formation,whereas (2)Wnt signalingmostly serves to syner-
gistically promote DE formation andmay require additional
factors to suppress pluripotency. FBS, which is commonly
added in presence ofWNT3A, could be promoting both dif-
ferentiation and suppressing pluripotency.
Although the use of GSK-3 inhibitors results in a downre-
gulation of E-CADHERIN/CDH1 and pluripotency factors
SOX2 and NANOG, and GSK-3 inhibition activates down-
streamWnt signaling, the inhibition ofGSK-3 could poten-
tially affect other signaling pathways in which GSK-3 is
active, such as cellular proliferation and migration (Doblein-Induced DE Formation with Comparable Efficiencies
, SOX17, FOXA2) markers in hiPSCs differentiated for 3 days in the
/ml) or (B) no growth factor (A0), 100 ng/ml Activin alone (A100),
mM CHIR99021 (C3), or 1.5 mM BIO (Bio1.5). Asterisk (*) indicates
resent SD of three biological replicates.
yses in undifferentiated hiPSCs or after differentiation of hiPSCs for
1.5, or A100 W30 + 0.5% FBS. A, Activin; B, BMP4; W, WNT3A; C,
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Comparable DE formation via Wnt or BMP Signalingand Woodgett, 2003). This is in contrast to the specific
WNT3A-induced Wnt signaling. In our experiments, we
also observed that WNT3A (up to 200 ng/ml) was not as
effective as the GSK-3 inhibitors in elevating b-catenin
transcript expression during DE differentiation (data not
shown). This could imply that WNT3A-induced Wnt
signaling events occurred solely at the protein level.
Further, this suggests that GSK-3 inhibitors potentiate the
increased presence of b-catenin, thereby strengthening
Wnt signaling (besides inhibiting the GSK-3-containing
destruction complex). Therefore, the inhibition of multi-
functional GSK-3 coupled with the increased b-catenin
expression could partly account for the differences
observed between WNT3A-induced and GSK-3 inhibi-
tion-induced Wnt signaling. Specific to CHIR99021 (a
potent and highly selective GSK-3 inhibitor as compared
to BIO), the strong inductive effects on mesendodermal
(EOMES, MIXL1, BRACHYURY) marker gene expression
(Kubo et al., 2004; Tada et al., 2005) and amarginal increase
in mesodermal marker TBX6 indicate that excessive Wnt
signaling via CHIR99021 (>3 mM) is likely to promote
mesoderm while suppressing DE formation.
Taken together, CHIR99021 appears to be the preferred
choice in combination with Activin (rank 1, Figure 4D)
in generatingDE cells based on its superior ability to induce
mesendoderm as well as its cost effectiveness (2 cents/ml
of media). BMP4 would be favored if not for its 20-fold
greater cost (rank 2, Figure 4D), whereas BIO, although
less expensive, exhibits cytotoxic effects (rank 3, Figure 4D)
and WNT3A is both expensive and requires a high dose to
be effective (rank 4, Figure 4D).
In summary, we demonstrate that both Wnt and BMP
can cooperate with Activin signaling to induce DE with
comparable efficiencies in a chemically defined serum-
free medium. DE generated from both Wnt+Activin and
BMP+Activin signaling can give rise to derivatives such as
pancreatic progenitor cells (Kunisada et al., 2012; Teo
et al., 2012). Thus, DE made via these two differing
signaling pathways is conceptually consistent and physio-Figure 4. BMP4, CHIR99021 and BIO Are More Effective at Suppr
(A) Western blot analyses for CDH1, SOX2, and ACTB protein levels in
increasing doses of BMP4 (B), WNT3A (W), CHIR99021 (C), or BIO (B
(B) Immunostaining for SOX2 and NANOG pluripotency factors on hiP
either 25 ng/ml BMP4 (B25), 100 ng/ml WNT3A (W100), 3 mM CHIR9
fetal bovine serum (FBS). Scale bar represents 50 mm.
(C) The percentage of SOX2+ and NANOG+ cells after differentiation o
A100 C3, A100 Bio1.5, or A100 W30 + 0.5% FBS. Asterisk (*) indicat
biological replicates.
(D) Summary of growth factor combination choice for DE induction ba
A100 B25 (rank 2) and then A100 Bio1.5 (rank 3) or A100 W100 (r
CHIR99021 costs2 cents, BMP4 costs48 cents, BIO costs1 cent,
cytotoxic effects. Scale bar represents 200 mm. A, Activin; B, BMP4;
endoderm; and hPSC, human pluripotent stem cell. DAPI is the nuclelogically relevant. Future genome-wide comparisons could
reveal interesting mechanistic insights specific to Wnt and
BMP signaling that are relevant for DE specification.EXPERIMENTAL PROCEDURES
Cell Culture
hiPSCs derived fromAG16102 skin fibroblasts (Coriell Institute) or
hESCs (CHB8) were cultured in conditions as described previously
(Teo et al., 2013b). To initiate DE differentiation, hiPSCs were
treated with Collagenase IV and Dispase at 1:1 ratio for 3–5 min
before being manually passaged into small clumps and placed in
a 70 mmcell strainer to deplete the feeders (Teo et al., 2012). hiPSCs
were then differentiated 2 days later in RPMI 2% B27 (no vitamin
A; serum-free chemically definedmedium; Teo et al., 2012) supple-
mented with the appropriate growth factors and chemical com-
pounds. Cells were harvested after 3 days of differentiation. To
generate pancreatic progenitors, DE was further differentiated
with 50 ng/ml Activin for 2 days, 50 ng/ml fibroblast growth fac-
tor-2 (FGF2), 3 mM all-trans retinoic acid (RA), and 10 mM nicotin-
amide (NIC) for 5 days; 50 ng/ml FGF2, 3 mMRA, 10 mMNIC, and
20 mM DAPT for 4 days; and 50 ng/ml FGF2, 10 mM NIC, and
20 mM DAPT for 3 days.qRT-PCR, Immunostaining, Western Blot,
and FACS Analyses
Methods for qRT-PCR, immunostaining, western blot, and FACS
analyses have been described previously (Teo et al., 2012,
2013b). The percentage of DE and pluripotent cells was obtained
by dividing the number of SOX17+, SOX2+, and NANOG+ cells
over the total number of DAPI+ cells. The average of three separate
images was used for cell counting analyses. A p value <0.05 indi-
cates statistical significance by Student’s t test. All error bars repre-
sent SD of three biological replicates in at least two independent
experiments. Primers and antibodies are provided in Table S2.
SUPPLEMENTAL INFORMATION
Supplemental Information includes four figures and two tables
and can be found with this article online at http://dx.doi.org/10.
1016/j.stemcr.2014.05.007.essing E-CADHERIN and Pluripotency as Compared to WNT3A
hiPSCs differentiated for 3 days in 100 ng/ml Activin A (A100) plus
io).
SCs differentiated for 3 days in the presence of A100 or A100 plus
9021 (C3), 1.5 mM BIO (Bio1.5), or 30 ng/ml WNT3A (W30) + 0.5%
f hiPSCs for 3 days in the presence of A100, A100 B25, A100 W100,
es p < 0.05 compared to A100. All error bars represent SD of three
sed on cost effectiveness. A100 C3 (rank 1) is preferred followed by
ank 4). A100 is least preferred (rank 5). For every 1 ml of media,
and WNT3A costs$2.30. BIO is less preferred than BMP4 due to its
W, WNT3A; C, CHIR99021; FBS, fetal bovine serum; DE, definitive
ar stain.
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